JPS6341889B2 - - Google Patents
Info
- Publication number
- JPS6341889B2 JPS6341889B2 JP10508180A JP10508180A JPS6341889B2 JP S6341889 B2 JPS6341889 B2 JP S6341889B2 JP 10508180 A JP10508180 A JP 10508180A JP 10508180 A JP10508180 A JP 10508180A JP S6341889 B2 JPS6341889 B2 JP S6341889B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- liver function
- present
- improving agent
- function improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003908 liver function Effects 0.000 claims description 15
- 241000251730 Chondrichthyes Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 4
- 229940040511 liver extract Drugs 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000284 extract Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241001552704 Centrophorus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001416185 Carcharias Species 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 241001656095 Echinorhinus brucus Species 0.000 description 1
- 241000251729 Elasmobranchii Species 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000795610 Parmaturus pilosus Species 0.000 description 1
- 241001416164 Squalidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10508180A JPS5731619A (en) | 1980-08-01 | 1980-08-01 | Improver for liver function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10508180A JPS5731619A (en) | 1980-08-01 | 1980-08-01 | Improver for liver function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5731619A JPS5731619A (en) | 1982-02-20 |
| JPS6341889B2 true JPS6341889B2 (de) | 1988-08-19 |
Family
ID=14397972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10508180A Granted JPS5731619A (en) | 1980-08-01 | 1980-08-01 | Improver for liver function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5731619A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1296322C (en) * | 1986-08-21 | 1992-02-25 | Takuo Kosuge | Active principle isolated from shark tissue |
-
1980
- 1980-08-01 JP JP10508180A patent/JPS5731619A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5731619A (en) | 1982-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5087280B2 (ja) | 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 | |
| FR2619718A1 (fr) | Nouvelles formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale | |
| NL192204C (nl) | Werkwijze voor het bereiden van isosilybine-vrij silibinine en farmaceutisch preparaat dat isosilybine-vrij silibinine bevat. | |
| JPS60132921A (ja) | ホスファチジルセリン医薬組成物 | |
| KR100860703B1 (ko) | 뇌경색 예방 및 치료용 약제의 제조에서엘-부틸프탈라이드의 용도 | |
| CN1210025C (zh) | 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物 | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| US7947283B2 (en) | Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides | |
| Meeran et al. | Chloroquine poisoning. Rapidly fatal without treatment. | |
| CN110621330A (zh) | 治疗b型肝炎的方法 | |
| JPS6341889B2 (de) | ||
| US5153221A (en) | Method for the treatment of acquired immune deficiency syndrome | |
| JPS6263517A (ja) | 肝臓疾患治療剤 | |
| EP1395270B1 (de) | Verwendung von phyllanthusbestandteilen zur herstellung eines arzneimittels zur prävention oder behandlung von infekten durch resistente hepatitis b-viren | |
| CN113082106A (zh) | 一种复方组合物及其在制备治疗糖尿病并发症的药物中的应用及治疗糖尿病并发症的药物 | |
| KR100516560B1 (ko) | 혈당강하 및 진통제 조성물 | |
| EP0707477B1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| JP7257091B2 (ja) | 認知症の治療及び予防薬 | |
| JPH1121234A (ja) | 抗肝炎剤 | |
| JPH0522687B2 (de) | ||
| CN111362896B (zh) | 红花黄色素及其在制备治疗心脑血管疾病药物中的应用 | |
| JPH10251154A (ja) | 肝炎抑制組成物 | |
| WO2005110393A1 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| FR2709964A1 (fr) | Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès. | |
| CN115350214A (zh) | 去除蓝布正乙醇水提取物中的肝毒性方法 |